Literature DB >> 8484679

Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity.

R Madhok1, A Crilly, J Watson, H A Capell.   

Abstract

In rheumatoid synovium interleukin 6 (IL-6) is the most abundantly expressed cytokine. Increased serum levels have been previously reported in patients with rheumatoid arthritis (RA). In this study serum IL-6 levels were measured in a well defined cohort using a bioassay (B9 cells) and levels were correlated with conventional clinical and laboratory indices of disease activity. Levels were significantly higher in serum from patients with RA (median 55 IU/ml; interquartile range 28-139) compared with serum from disease (median 7 IU/ml; 1-23) and normal controls (median 10 IU/ml; 7-12). No difference was observed between men and women. Levels did not correlate with disease duration. Significant associations were observed between IL-6 and C reactive protein and between the Ritchie articular index and duration of morning stiffness. No other correlations were observed. The value of these findings in the monitoring of RA and as an indicator of response to second line treatment needs to be established.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8484679      PMCID: PMC1005024          DOI: 10.1136/ard.52.3.232

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  12 in total

1.  Value of joint scintigraphy in the prediction of erosiveness in early rheumatoid arthritis.

Authors:  T T Möttönen; P Hannonen; J Toivanen; A Rekonen; M Oka
Journal:  Ann Rheum Dis       Date:  1988-03       Impact factor: 19.103

2.  IL-6/IFN-beta 2 in synovial effusions of patients with rheumatoid arthritis and other arthritides. Identification of several isoforms and studies of cellular sources.

Authors:  N Bhardwaj; U Santhanam; L L Lau; S B Tatter; J Ghrayeb; M Rivelis; R M Steinman; P B Sehgal; L T May
Journal:  J Immunol       Date:  1989-10-01       Impact factor: 5.422

3.  Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis.

Authors:  P A Guerne; B L Zuraw; J H Vaughan; D A Carson; M Lotz
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

4.  Transforming growth factor beta 1 regulates production of acute-phase proteins.

Authors:  A Mackiewicz; M K Ganapathi; D Schultz; A Brabenec; J Weinstein; M F Kelley; I Kushner
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

5.  Articular indices of joint inflammation in rheumatoid arthritis. Correlation with the acute-phase response.

Authors:  P W Thompson; A J Silman; J R Kirwan; H L Currey
Journal:  Arthritis Rheum       Date:  1987-06

6.  Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis.

Authors:  B Dasgupta; M Corkill; B Kirkham; T Gibson; G Panayi
Journal:  J Rheumatol       Date:  1992-01       Impact factor: 4.666

7.  Interleukin-6 (IL-6) in synovial fluid and serum of patients with rheumatic diseases.

Authors:  A J Swaak; A van Rooyen; E Nieuwenhuis; L A Aarden
Journal:  Scand J Rheumatol       Date:  1988       Impact factor: 3.641

8.  Functional discrimination between interleukin 6 and interleukin 1.

Authors:  M Helle; L Boeije; L A Aarden
Journal:  Eur J Immunol       Date:  1988-10       Impact factor: 5.532

9.  Relationships between local inflammation, interleukin-6 concentration and the acute phase protein response in arthritis patients.

Authors:  I Holt; R G Cooper; S J Hopkins
Journal:  Eur J Clin Invest       Date:  1991-10       Impact factor: 4.686

10.  Dual control of C-reactive protein gene expression by interleukin-1 and interleukin-6.

Authors:  U Ganter; R Arcone; C Toniatti; G Morrone; G Ciliberto
Journal:  EMBO J       Date:  1989-12-01       Impact factor: 11.598

View more
  107 in total

1.  Intravenous iron therapy is the option for RA patient with absolute iron deficiency accompanied with functional iron deficiency.

Authors:  Jing Tan; Jing Wei
Journal:  Clin Rheumatol       Date:  2012-05-31       Impact factor: 2.980

Review 2.  Interleukin-6 in aging and chronic disease: a magnificent pathway.

Authors:  Marcello Maggio; Jack M Guralnik; Dan L Longo; Luigi Ferrucci
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2006-06       Impact factor: 6.053

3.  Tocilizumab.

Authors:  Clemens Scheinecker; Josef Smolen; Uma Yasothan; Jeffrey Stoll; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2009-04       Impact factor: 84.694

4.  Efficacy of tocilizumab on MRI-determined bone oedema in rheumatoid arthritis.

Authors:  Nada Bensaoud; Samira Rostom; Rachid Bahiri; Najia Hajjaj-Hassouni
Journal:  Clin Rheumatol       Date:  2015-04-23       Impact factor: 2.980

Review 5.  Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody.

Authors:  K Yoshizaki; N Nishimoto; M Mihara; T Kishimoto
Journal:  Springer Semin Immunopathol       Date:  1998

6.  Modulation of C-reactive protein and tumour necrosis factor-α in collagen-induced arthritis in Dark Agouti rats: impact of collagen concentration on severity of arthritis.

Authors:  Dulanthi Tudave; Ammu Radhakrishnan; Srikumar Chakravarthi; Nagaraja Haleagrahara
Journal:  Inflamm Res       Date:  2011-06-02       Impact factor: 4.575

7.  Inhibiting interleukin-6 in rheumatoid arthritis.

Authors:  Ernest Choy
Journal:  Curr Rheumatol Rep       Date:  2008-10       Impact factor: 4.592

8.  Effects of exposure to hyperbaric oxygen on oxidative stress in rats with type II collagen-induced arthritis.

Authors:  F Nagatomo; N Gu; H Fujino; T Okiura; F Morimatsu; I Takeda; A Ishihara
Journal:  Clin Exp Med       Date:  2009-09-25       Impact factor: 3.984

Review 9.  Biologic treatments for systemic rheumatic diseases.

Authors:  Y Shirota; G G Illei; N P Nikolov
Journal:  Oral Dis       Date:  2008-02-14       Impact factor: 3.511

Review 10.  Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor.

Authors:  Jean-Michel Dayer; Ernest Choy
Journal:  Rheumatology (Oxford)       Date:  2009-10-23       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.